Silence Therapeutics’ (SLN) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Silence Therapeutics (NASDAQ:SLN) in a research note released on Friday morning,Benzinga reports. HC Wainwright currently has a $75.00 target price on the stock.

A number of other equities analysts also recently weighed in on the company. Morgan Stanley reissued an “overweight” rating and set a $49.00 price target on shares of Silence Therapeutics in a research report on Tuesday, October 8th. Chardan Capital reissued a “buy” rating and set a $55.00 target price on shares of Silence Therapeutics in a report on Thursday. Finally, Jefferies Financial Group began coverage on Silence Therapeutics in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $40.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $57.20.

Silence Therapeutics Stock Down 9.2 %

Shares of Silence Therapeutics stock opened at $12.70 on Friday. The stock has a market cap of $380.11 million, a P/E ratio of -8.09 and a beta of 1.30. Silence Therapeutics has a 12-month low of $8.94 and a 12-month high of $27.72. The business’s 50 day moving average is $17.98 and its 200-day moving average is $19.12.

Silence Therapeutics (NASDAQ:SLN) last posted its quarterly earnings results on Thursday, August 15th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.10). Silence Therapeutics had a negative return on equity of 65.18% and a negative net margin of 342.00%. The firm had revenue of $0.76 million for the quarter, compared to the consensus estimate of $11.28 million. On average, sell-side analysts expect that Silence Therapeutics will post -1.55 EPS for the current year.

Institutional Trading of Silence Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Y Intercept Hong Kong Ltd raised its position in shares of Silence Therapeutics by 22.9% in the third quarter. Y Intercept Hong Kong Ltd now owns 21,078 shares of the company’s stock valued at $383,000 after buying an additional 3,923 shares in the last quarter. Point72 Asset Management L.P. increased its position in shares of Silence Therapeutics by 219.3% in the third quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company’s stock worth $8,505,000 after purchasing an additional 321,300 shares during the period. Parkman Healthcare Partners LLC raised its stake in Silence Therapeutics by 71.8% in the third quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company’s stock valued at $9,051,000 after purchasing an additional 208,029 shares in the last quarter. Ikarian Capital LLC lifted its position in Silence Therapeutics by 15.9% during the third quarter. Ikarian Capital LLC now owns 587,343 shares of the company’s stock worth $10,678,000 after purchasing an additional 80,678 shares during the period. Finally, Janus Henderson Group PLC increased its holdings in Silence Therapeutics by 32.8% in the 3rd quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock valued at $19,798,000 after buying an additional 268,250 shares during the period. Institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.